Hermann is member of T-CURX’s scientific advisory board. He is one of the leading Hematologist/Oncologists in Europe and an renowned international clinical oncologist with a focus on hematological malignancies. He is Director of the Medical Clinic and Department of Medicine II and the Comprehensive Cancer Center at the University Hospital Würzburg. Under his leadership, The University Hospital Würzburg and his Department is a German reference center for the hematologic cancer multiple myeloma.

Hermann and his Department is leading many clinical trials with first in class and innovative biologic drug modalities to treat cancer, like e.g. bispecific antibodies, immune checkpoint inhibitors or adoptive cellular therapies. In addition, Prof. Einsele is Vice-President Research at the University of Würzburg and Dean of the Faculty of Medicine.

Hermann is international key opinion leader in hematology and oncology with particular expertise in multiple myeloma, adoptive immunotherapy, allogeneic bone marrow transplantation (allo HCT), as well as a pioneer in T-cell therapy. He was first to use adoptive transfer of cytomegalovirus (CMV)-specific T cells to treat infections after allo HCT in Europe and performed clinical trials of immunotherapy with gamma-delta T cells to treat AML and multiple myeloma. He is constantly ranked as one of Europe’s Top-Physicians in his field and has a strong track record with > 350 peer-reviewed publications in top-tier scientific and medical journals.

He is board member of the European Society for Blood and Marrow Transplantation (EBMT), the German Society for Hematology and Oncology (DGHO) and leader of the German Multiple Myeloma study group (DSMM).